# CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update
Ticker: CTMX
Company: CytomX Therapeutics, Inc.
Source: CytomX Therapeutics, Inc.
Published: 2026-05-07 20:15 EST
Original Source URL: https://ir.cytomx.com
## Summary

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose

## Article Body
- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose
## Recent Company News
- 2026-06-03 12:00 EST — [CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer](https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer) — Source: CytomX Therapeutics, Inc.
- 2026-05-21 12:00 EST — [CytomX Therapeutics to Present at Upcoming June Investor Conferences](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences) — Source: CytomX Therapeutics, Inc.
- 2026-05-18 12:00 EST — [CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-mamata-gokhale-ph-d-rac-as-senior-vice-president-of-regulatory-affairs) — Source: CytomX Therapeutics, Inc.
- 2026-05-07 20:15 EST — [CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update) — Source: CytomX Therapeutics, Inc.
- 2026-04-30 12:00 EST — [CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2026-financial-results-on-may-7-2026) — Source: CytomX Therapeutics, Inc.
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)